| Sumario: | Background: The presence of numerous antibiotic-resistance mechanisms in Gram-positive and Gram-negative bacteria is a global concern, which is further complicated by emergence of newer mechanisms in recent years. Few new compounds are in the production-pipeline that show potential for usage as antimicrobial agents. Antibiotic adjuvant ceftriaxone-disodium edetate-sulbactam, available under tradename Elores™, showed potential in this study by demonstrating antimicrobial activity against various multidrugresistant bacteria. Methods: In this prospective in-vitro study, we tested the antimicrobial activity of Elores™ against a battery of clinical Gram-positive and Gram-negative bacterial isolates, including antibiotic-susceptible and antibiotic-resistant bacteria such as ESBL-producing Enterobacterales (ESBLPE), carbapenem-resistant Enterobacterales (CRE), Enterobacterales showing colistin-resistance (ECR), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE). Results: Elores™ showed excellent activity against the tested Gram-positive and Gram-negative bacterial species, including some highly resistant species such as ESBL-producers, CRE, species resistant to colistin, MRSA and VRE. Elores™ was non-inferior to tigecycline in VRE isolates and non-inferior to colistin in Escherichia coli, Citrobacter species, Pseudomonas aeruginosa and Acinetobacter baumannii. However, in Klebsiella species the activity of Elores™ was notably better than colistin. Conclusions: In addition to activity against ESBL-producers and CRE, the activity of Elores™ against colistin-resistant Enterobacterales, MRSA and VRE showed promise, indicating its use as a potential candidate for empirical therapy due to its high activity against multidrug-resistant Gram-positive and Gram-negative bacteria.
|
|---|